A new Perspective published in npj Digital Medicine from CCAIM brings together academic and industry partners, led by Professor Mihaela van der Schaar, to explore how causal inference and digital twins could support more adaptive, efficient and patient-centred clinical trials.
The annual CCAIM Symposium showcased cutting-edge research from across the CCAIM community while bringing together experts from academia, healthcare and industry to discuss the future of AI in biomedicine.
AI-enabled clinical trials have been a core pillar of CCAIM’s vision from the beginning. Discover the research advancing more adaptive, personalised and intelligent clinical development.
Professor Mihaela van der Schaar will deliver a State-of-the-Art Keynote at EASL Congress 2026 in Barcelona, where she will discuss cutting-edge machine learning for liver health and how AI can move beyond static prediction toward systems that reason about disease progression, treatment response, patient heterogeneity, and clinical decision-making.
Nicolas Huynh and Prof David Bentley discuss their AISTATS 2026 paper on interpretable DNA sequence analysis, introducing DEFT — a framework that brings together accuracy and interpretability in genomics.
On 24 February 2026, CCAIM and Cambridge University Health Partners co-hosted “Partnering with Cambridge: AI to Revolutionise Clinical Trials” at the Ray Dolby Centre. The event brought together leaders from academia, industry, and regulation, marking an important first step in building closer collaboration around AI-enabled clinical trials.
Researchers from the Cambridge Centre for AI in Medicine have had a total of 11 papers accepted for the thirty-ninth Conference on Neural Information Processing Systems (NeurIPS) at the San Diego Convention Centre, 2 – 7 December 2025.
The CCAIM has published a landmark manifesto outlining how AI technologies – causal inference and digital twins – can transform clinical trials. This collaborative publication, co-authored with all CCAIM strategic partners – AstraZeneca, GSK, Sanofi, Boehringer Ingelheim, and QuantumBlack – charts a roadmap for faster, safer, and more inclusive medical research.
We are pleased to announce that Prof Mihaela van der Schaar has been appointed as the Spinoza Guest Professor at Amsterdam UMC. During March, she will deliver lectures on the future of AI, a master class exploring its transformative potential in healthcare and beyond, and first and foremost meet researchers and students in Amsterdam. It’s… Read More »Mihaela van der Schaar appointed as Spinoza Guest Professor at Amsterdam UMC
Researchers from the Cambridge Centre for AI in Medicine are presenting a record-breaking 17 papers at the thirty-eighth Conference on Neural Information Processing Systems (NeurIPS) at the Vancouver Convention Center, 10 – 15 December 2024. In the below document, we present a comprehensive overview of the CCAIM contributions, papers, and workshop participations for 2023. We… Read More »CCAIM at NeurIPS 2024
Ready for the next big leap in making AI truly accessible? Today, we are excited to release CliMB, our no-code AI-enabled partner for clinical predictive modelling. Despite the significant promise, real-world applications of cutting-edge machine learning remain limited. In fact, clinician scientists face substantial barriers in accessing state-of-the-art tools. While AutoML has been designed as… Read More »CliMB: An AI-enabled Partner for Clinical Predictive Modelling
The Cambridge Centre for AI in Medicine (CCAIM) is pleased to announce a groundbreaking strategic partnership with leading pharmaceutical companies AstraZeneca, Boehringer Ingelheim, and GSK. This collaboration aims to harness the power of artificial intelligence and machine learning to drive innovation in medical research and improve patient outcomes worldwide. Key Objectives of the Partnership: Innovative… Read More »CCAIM Announces Strategic Partnership with Industry Leaders
A new Perspective published in npj Digital Medicine from CCAIM brings together academic and industry partners, led by Professor Mihaela van der Schaar, to explore how causal inference and digital twins could support more adaptive, efficient and patient-centred clinical trials.
